Analytical Data
-
Gene name
CDKL2
-
简介
Cyclin-dependent kinase-like 2 (CDKL2), is a member of the CDC2-related serine/threonine protein kinase family. CDKL2 is tightly associated with tumor progression and is a regulator of epithelial-mesenchymal transition (EMT). CDKL2 also plays a role in cognitive functions, emotion, and neurological disorders[1][2]. CDKL2 Protein, Human (sf9, His) is the recombinant human-derived CDKL2 protein, expressed by Sf9 insect cells , with N-His labeled tag.
- Application
-
Alternative Names
Cyclin-dependent kinase-like 2; Protein kinase p56 KKIAMRE; CDKL2
-
Species
Human
-
Source
Baculovirus
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q92772
-
Expression Region
M1-H493
-
Protein Length
Full Length
-
Molecular Weight
63 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDKL2 (Cyclin-dependent kinase-like 2) is a serine/threonine kinase that plays a crucial role in regulating cellular processes such as cell cycle progression, neuronal differentiation, and synaptic transmission. Mutations and dysregulation of CDKL2 have been implicated in various neurodevelopmental disorders, including intellectual disability and epilepsy. Given its significant role in neuronal function, the study of CDKL2 recombinants has garnered interest for potential therapeutic applications. Recombinant CDKL2 proteins are essential for elucidating the structure-function relationships of this kinase, as well as for exploring its biological pathways. Advances in recombinant protein technology allow researchers to produce CDKL2 in sufficient quantities for biochemical assays, enabling the investigation of its enzymatic activity and interactions with other cellular components. Understanding the biophysical properties and regulatory mechanisms of CDKL2 may lead to novel insights into its role in disease pathology and identify biomarkers for early diagnosis and therapeutic targets. Therefore, the study of CDKL2 recombinant proteins is not only pivotal for basic neurological research but also holds promise for developing innovative treatment strategies for conditions associated with CDKL2 dysfunction.
